3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
25
Lymphoma, Large B-Cell, Diffuse
24
Burkitt Lymphoma
19
Lymphoma, Follicular
14
Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Neoplasms
8
Lymphoma, Non-Hodgkin
8
Lymphoma, B-Cell
6
Recurrence
5
Prostatic Neoplasms, Castration-Resistant
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Biphenotypic, Acute
4
Ovarian Neoplasms
3
Lymphoproliferative Disorders
3
Lymphoma, T-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Prostate Cancer Metastatic
2
Plasmablastic Lymphoma
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Enteropathy-Associated T-Cell Lymphoma
2
Interventions
Cyclophosphamide
5
ibrutinib
4
fludarabine
4
pirtobrutinib
3
obinutuzumab
3
acalabrutinib
3
fludarabine phosphate
2
Rituximab
2
Mesna
2
venetoclax
1
ricolinostat
1
idelalisib
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Melphalan
1
Leukapheresis
1
Doxorubicin
1
Diet
1
Busulfan
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Prednisone
×
90 days
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled